PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.
The proprotein convertase PCSK9, a target for the treatment of hypercholesterolemia, is a negative regulator of the LDL receptor (LDLR) leading to its degradation in endosomes/lysosomes and up-regulation of plasma LDL-cholesterol levels. The proprotein convertases, a family of nine secretory serine...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science (PLoS)
2013-01-01
|
| coleção: | PLoS ONE |
| Acesso em linha: | http://europepmc.org/articles/PMC3741231?pdf=render |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|